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Simultaneous evolutionary expansion and
constraint of genomic heterogeneity in multifocal
lung cancer
Pengfei Ma1, Yujie Fu2, Mei-Chun Cai3, Ying Yan4, Ying Jing1, Shengzhe Zhang1, Minjiang Chen5, Jie Wu6,
Ying Shen7,8, Liang Zhu7,8, Hong-Zhuan Chen7,8, Wei-Qiang Gao1, Mengzhao Wang5, Zhenyu Gu4,
Trever G. Bivona9,10, Xiaojing Zhao2 & Guanglei Zhuang1,11
Recent genomic analyses have revealed substantial tumor heterogeneity across various
cancers. However, it remains unclear whether and how genomic heterogeneity is constrained
during tumor evolution. Here, we sequence a unique cohort of multiple synchronous lung
cancers (MSLCs) to determine the relative diversity and uniformity of genetic drivers upon
identical germline and environmental background. We find that each multicentric primary
tumor harbors distinct oncogenic alterations, including novel mutations that are experi-
mentally demonstrated to be functional and therapeutically targetable. However, functional
studies show a strikingly constrained tumorigenic pathway underlying heterogeneous genetic
variants. These results suggest that although the mutation-specific routes that cells take
during oncogenesis are stochastic, genetic trajectories may be constrained by selection for
functional convergence on key signaling pathways. Our findings highlight the robust evolu-
tionary pressures that simultaneously shape the expansion and constraint of genomic
diversity, a principle that holds important implications for understanding tumor evolution and
optimizing therapeutic strategies.
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A prevailing view of cancer holds that it is an evolutionarydisease initiated by sporadic oncogenic alterations thatcause pre-malignant cells to propagate faster and better
survive stress than normal cells, resulting in tumor establish-
ment1, 2. Many established tumors are genetically unstable,
creating a tendency to accumulate additional mutations; as a
result, the constituent malignant cells within a tumor are con-
stantly evolving3, 4. One consequence of these forces is substantial
genomic divergence that causes extensive intratumoral hetero-
geneity and branching phylogenies5–10. Cumulative evidence is
emerging that the genetic complexity and molecular evolution of
a tumor profoundly impact the clinical course of individuals who
suffer from many different cancer types11, 12.
One of the pivotal, yet largely under-investigated aspects in the
framework of this general scheme is to what extent the genomic
diversity present in a tumor contributes to phenotypic hetero-
geneity13. It has been generally accepted that the myriad of cancer
genetic repertoires can permit phenotypic plasticity, allowing the
tumor to dynamically adapt to local and systemic pressures
including those exerted by treatments11, 14, 15. However, it is still
possible that under a given circumstance evolutionary constraints
may apply to restrict tumor genetic drivers to limited options and
lead to phenotypic convergence. There has been preliminary
evidence to support this hypothesis. For example, different tumor
subclones or distinct metastatic sites were occasionally shown to
undergo parallel evolution of the same gene, pathway or protein
complex during carcinogenesis or drug treatment16–19. Similarly,
four independent tumors occurring in a patient with Von Hippel
Lindau syndrome exhibited functionally recurrent activation of
the mTOR pathway20. One caveat of these studies is that the
tumor clones or subclones studied shared largely identical
somatic alterations or well-known germline cancer-predisposition
genes, which may potentially define an intrinsic boundary for
evolutionary divergence. From a therapeutic perspective, an
improved understanding of the competing forces controlling on
the one hand the expansion, and on the other hand the constraint
of genomic diversity and heterogeneity during tumor evolution is
essential to precisely decipher the Achilles’ heels of human can-
cers for rational intervention.
MSLC is diagnosed as multiple tumor nodules in the same or
different lung lobes21, 22; thus, MSLCs by definition share an
identical germline genetic background and environmental expo-
sure in individual patients. MSLC is a frequent occurrence in
individuals with lung cancer23–25, yet the molecular origins and
relationships among the synchronous tumors remain largely
unclear in most patients26–28. We reasoned that the genomic
analysis of MSLC to determine the extent of common versus
divergent ancestry, an under-investigated area to date, would
offer a unique opportunity to provide insights into the evolu-
tionary principles that shape tumorigenesis.
In this study, we present a detailed genetic and experimental
analysis on a collection of clinical specimens from patients with
MSLCs. Whole-exome sequencing reveals independent clonality
of synchronous lesions in each individual and profound genomic
heterogeneity at both interfocal and intrafocal levels. However,
the functional convergence of distinct oncogenic drivers on key
signaling pathways within multicentric primary tumors is evident
as a possibly generalizable principle that can aid rational ther-
apeutic selection. Therefore, simultaneous evolutionary expansion
and constraint of genomic heterogeneity may competitively and
collaboratively shape tumorigenesis of lung cancer and potentially
other human malignancies.
Results
Clonal architecture and mutational landscape of MSLC. To
gain further insights into the genetic alterations shaping lung
tumorigenesis, we sampled four patients (RJLC1-4; Table 1) with
treatment-naive MSLC (16 tumor samples within 11 independent
lesions, all adenocarcinomas) and performed whole-exome
sequencing on tumor and matched adjacent normal lung DNA
(Supplementary Fig. 1), yielding a mean coverage of 244×
(205×−296×). Approximately 99% of targeted bases were covered
to a depth of 20× or more (Supplementary Table 1). We identified
167–679 somatic alterations per tumor (Supplementary Data 1),
including a total of 373 non-synonymous exonic mutations pre-
sent in at least one tumor region. In order to determine whether
MSLC was derived from one single lesion with intra-thoracic
metastases or multiple local primary tumors, non-silent muta-
tions were mapped on the basis of their intertumoral distributions
and classified as shared (present in more than one tumor) or
private (present in only one tumor) alterations. In addition, we
constructed phylogenetic trees to estimate the ancestral rela-
tionships of individual foci (Fig. 1a). In agreement with a recent
study demonstrating independent clonal origins of MSLCs28,
significantly overlapping variant sets were absent between any
tumor pair in each of these four patients. As a comparison, multi-
region sequencing of two larger lesions (RJLC1-T1 and RJLC4-
T1) revealed many shared somatic mutations among sequenced
samples within the same tumor (Fig. 1a). This observation sug-
gests that multiple pulmonary nodules within one subject prob-
ably arose autonomously from different progenitor cells.
The mutation spectra of single-nucleotide variations (SNVs)
were fairly consistent across lung cancers from the same
individuals; however, notable discordance was observed among
the three tumors of patient RJLC3. The majority of sequenced
samples displayed a preponderance of C> T and T>G
transversions, but not C>A transitions associated with tobacco
exposure29, consistent with the non-smoking history of these
patients (Fig. 1b). We detected genetic aberrations involving
genes previously reported to be recurrently altered in lung
adenocarcinoma30, including EGFR, KRAS, MET, BRAF, and
TP53. Other identified putative driver mutations often affected
genes regulating transcription, MAPK signaling, cell adhesion
and survival (Fig. 1b; Supplementary Table 2). Overall, few driver
mutations were shared between any two tumors, further
suggesting that our MSLC cohort represented independently
arising primary tumors. Detailed analysis of mutational signa-
tures31 separated all specimens into two major clusters and
indicated that tumors from the same patient usually clustered
Table 1 Patient characteristics in the MSLC cohort
Patient ID Age Gender Ethnicity Smoking history Histology TNM stage Tumor sites (n)
RJLC1 64 Female Han Chinese Non-smoker AIS pTisN0M0 RUL(1) RLL(1)
RJLC2 52 Female Han Chinese Non-smoker AIS pTisN0M0 RUL(3)
RJLC3 57 Female Han Chinese Non-smoker AIS pTisN0M0 LUL(3)
RJLC4 60 Female Han Chinese Non-smoker ADC pT1N0M0 RUL(1) LUL(1) LLL(1)
ADC adenocarcinoma, AIS adenocarcinoma in situ, LLL left lower lobe, LUL left upper lobe, RLL right lower lobe, RUL right upper lobe
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together with the exception of RJLC3 (Fig. 1c; Supplementary
Fig. 2). This finding suggests that distinct mutational processes
were operating to promote tumorigenesis within different lesions
in this case. We further used the deconstructSigs framework to
extract known mutational signatures that might contribute to the
specific mutational profiles in each cluster32, 33. Interestingly,
cluster 1 exhibited an enrichment of signature 1 (age-related),
signature 3 (associated with failure of DNA double-strand break-
repair by homologous recombination), signature 9 (attributable to
polymerase η and implicated with AID activity), and signature 12
(unknown etiology). In striking contrast, cluster 2 was almost
exclusively characterized by signature 9 (Supplementary Fig. 3),
which had been described only in chronic lymphocytic leukemia
and malignant B-cell lymphoma and not previously in lung
cancer. Additional investigation is required to determine the
mechanistic underpinnings and biological significance of these
findings.
Interfocal and intrafocal genetic heterogeneity of MSLC. In-
depth genomic sequencing of MSLC enabled multi-layer deli-
neation of tumor heterogeneity at interpatient, interfocal and
intrafocal levels (Fig. 2a). In accordance with the genetically
heterogeneous TCGA lung cancers30, each MSLC patient had a
unique set of somatic variants, as exemplified by a distinct
mutation spectrum and largely non-overlapping exonic
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Fig. 1 Clonal architecture and mutational landscape of MSLC. a Computed tomography (CT) diagnosis and clonal architecture of multifocal tumors in four
MSLC patients. Heat maps showed the presence (blue) or absence (gray) of all non-silent somatic mutations in every tumor region. Phylogenetic trees
indicated the clonal structure of sequenced tumor regions in each patient. Scale bar, 1 cm. b Mutational landscape of all 16 sequenced tumor regions.
Putative driver genes with somatic mutations were classified according to the functional categories. c Frequencies for each of the six substitutions at all 16
possible trinucleotide contexts were displayed in a heat map. All specimens were separated into two major clusters based on the mutational signatures
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substitutions (Fig. 2b). Analysis of genetic (germline) predis-
position also failed to uncover meaningful single-nucleotide
polymorphisms (SNPs) associated with lung cancer susceptibility,
further highlighting the likely role of distinct somatic genetic
alterations in driving the genesis of each tumor.
To further corroborate the interfocal diversification revealed by
phylogenetic analysis, we functionally inferred the most promi-
nent cancer-driving abnormality in each tumor (Supplementary
Table 3; Supplementary Figs. 4–7). KRAS, a well-known proto-
oncogene, was mutated in RJLC2-T2 (KRASG12D) and RJLC3-T3
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(KRASG12C), which presumably resulted in constitutive MAPK
signaling. Similarly, RJLC1-T1, RJLC1-T2, and RJLC4-T1/T2/T3
harbored activating EGFR mutations (EGFRL858R or EGFRE746-
A750 del) or an ERBB2 in-frame insertion (HER2YMVA) to
potentiate oncogenic transformation. A MET mutation causing
exon 14 skipping in RJLC2-T3 (c-METΔE14), and ARAFS214C,
identified in RJLC3-T2, have been recently reported to be
oncogenic in preclinical models and lung adenocarcinoma
patients34–36. Indeed, we were able to experimentally validate
the tumorigenic potential of ARAFS214C, c-METΔE14, and
HER2YMVA (Supplementary Fig. 8a). Notably, alterations were
detected in both ERBB3 (also known as HER3) and PDGFRB
genes in RJLC2-T3 but we found that the variants did not lead to
substantial mutant-specific AKT or ERK hyperactivation (Sup-
plementary Fig. 8b). However, we noted two candidate clinically
relevant alterations located in protein kinase domains (Supple-
mentary Fig. 8c), BRAFD594G in RJLC2-T1 and MEK1E102-I103 del
(encoded by MAP2K1) in RJLC3-T1. Each mutant, despite being
previously discovered in various cancer types, had not been
explicitly implicated in driving lung malignancy. To characterize
the functional impact of the BRAF and MEK1 mutations, we
ectopically expressed mutant alleles in a human embryonic
kidney cell line HEK293T, an immortalized bronchial epithelial
cell line BEAS-2B and a lung adenocarcinoma cell line LXF-289,
using the KRASG12D oncogenic variant as a positive control.
Interestingly, BRAFD594G exhibited attenuated catalytic activity
toward downstream MAPK pathway in HEK293T (Supplemen-
tary Fig. 8d), consistent with its location in the highly conserved
DFG motif and previously reported kinase-inactivating nature37.
However, the transforming capability of BRAFD594G was evident
in BEAS-2B or LXF-289 cells presumably in a RAS/CRAF-
dependent manner37, as assessed by phospho-ERK, colony-
forming and xenograft tumorigenicity assays (Fig. 2c−e). On
the other hand, MEK1E102-I103 del clearly acted as a biochemical
gain-of-function mutation in all three cell lines (Fig. 2c−e) and
was associated with response to the MEK inhibitor trametinib
in vivo (Supplementary Fig. 8e). Importantly, we established a
patient-derived lung tumor xenograft model harboring
BRAFD594N, which likewise enhanced colony formation relative
to vector control or wild-type BRAF (Supplementary Fig. 8f). We
observed a remarkable sensitivity to MAPK pathway targeted
therapies, particularly the combination of dabrafenib and
trametinib (Supplementary Fig. 8g). These data collectively reveal
the oncogenicity and targetability of BRAFD594G and MEK1E102-
I103 del in lung cancer. Therefore, each multicentric primary
tumor could be driven by distinct molecular machinery and
interfocal heterogeneity was highly prevalent in MSLC. Further-
more, although all MSLCs exhibited positive staining of CD3
(Supplementary Fig. 9a), indicating that T cells already infiltrated
into tumors even in early-stage lung cancer, each lesion was
predicted to harbor distinct repertoires and unequal load of
neoantigens (Supplementary Fig. 9b; Supplementary Table 4),
suggestive of functionally heterogeneous tumor-associated lym-
phocytes and potentially differential clinical responses to immune
treatment regimens.
To estimate the extent of intrafocal heterogeneity in MSLC, we
first performed single-sample clonality analysis using PyClone38
(Supplementary Fig. 10) and SciClone39 (Supplementary Fig. 11).
Both methods consistently indicated that the majority of
sequenced specimens were oligoclonal (Supplementary Table 5).
Nevertheless, the key putative driver mutations were proven to be
mostly clonal on the basis of cancer cell fraction (the fraction of
tumor cells harboring the SNVs) (Fig. 2f), consistent with previous
reports showing that driver mutations occur early during lung
cancer development8. Additionally, two larger tumors (RJLC1-T1
and RJLC4-T1) were subjected to multi-region sequencing (M-
seq), permitting a comprehensive dissection of spatiotemporal
intrafocal evolution. Corroborating prior observations7, 8, phylo-
genetic reconstruction of the M-seq data yielded evidence of a
branched evolutionary pattern (Fig. 2g). The ITB (indices of
branched to truncal mutations) for these two tumors were
generally higher compared with those of lung adenocarcinomas
analyzed by M-seq recently (Supplementary Table 6). The spectra
of point mutations in each tumor displayed considerable temporal
difference between early (truncal) and late (branched) SNVs.
Consistent with previous reports7, 8, a relatively higher percentage
of somatic mutations could be ascribed to APOBEC-mediated
mutagenesis on the branches compared with the trunk in both
tumors (Supplementary Fig. 12). Moreover, spatial heterogeneity,
as indicated by divergent mutational signatures, was evident
among geographically separated tumor regions (Fig. 2g). Together,
these findings suggested that dynamic mutational processes
shaped subclonal genomes over time, conceivably contributing
to the substantial intrafocal heterogeneity observed in MSLC.
Constrained tumorigenic pathways among multicentric
lesions. We noted a striking biological convergence of hetero-
geneous driver events among individual foci on the same sig-
naling pathway in each MSLC case. For example, RJLC1 and
RJLC4 both altered the EGFR family of receptor tyrosine kinase,
whereas RJLC2 and RJLC3 tended to primarily impact on the
MAPK pathway (Fig. 3a; Supplementary Fig. 13a). While this
phenomenon was reminiscent of a previously described parallel
evolution principle11, 40, the functional forces that underlie this
striking biological convergence and its consequences on tumor-
igenesis and treatment response remain largely unresolved. For
instance, an important unanswered question in the field is whe-
ther individual, distinct genetic alterations that are present in
different tumors impart identical or disparate signaling outputs or
treatment responses. We therefore used this unique MSLC system
to test the hypothesis that different driver mutations in each
patient are functionally interchangeable, a principle that has been
implied but not formally demonstrated to date in lung cancer (to
our knowledge). We designed an experimental workflow to spe-
cifically control the lung cancer cell population using the clus-
tered regularly interspaced short palindromic repeats (CRISPR)-
Cas9 system (Fig. 3b). To this end, EGFRE746-A750 del was
knocked out in PC9 cells, which resulted in decreased phospho-
AKT and phospho-ERK. The EGFR-null PC9 cells could only
Fig. 2 Interfocal and intrafocal genetic heterogeneity of MSLC. a A schematic overview of tumor heterogeneity analysis at interpatient, interfocal and
intrafocal levels. b Mutation spectra of four MSLC patients were summarized by pie charts and shared mutations between different subjects were showed
in Venn diagram. c Overexpression of indicated wild-type or mutant genes in BEAS-2B or LXF-289 cells. Gene expression and ERK phosphorylation were
measured by immunoblotting. d Indicated wild-type or mutant genes were lentivirally introduced into BEAS-2B or LXF-289 cells. Cells were cultured for
two weeks and stained with crystal violet. Scale bar, 5 mm. e Tumor growth of BEAS-2B xenografts that ectopically expressed indicated mutant genes. Each
line represented mean tumor volume of the respective group, and error bars indicated standard deviation (10 mice per group). Scale bar, 10mm. f A heat
map presented the CCF of putative driver mutations in each sequenced region of the MSLC tumors. gMutation spectra of early mutations (trunk) and late
mutations (branch), and mutational signatures of different tumor regions in M-seq samples of RJLC1-T1 and RJLC4-T1
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survive a short period of time. When we introduced HER2YMVA
into these cells, the impaired AKT and ERK phosphorylation and
growth capacity were fully restored (Fig. 3c). Accordingly, sub-
stitution of EGFRE746-A750 del with HER2YMVA conferred insen-
sitivity to erlotinib, an EGFR inhibitor with less activity against
HER2, but not afatinib or dacomitinib, which each inhibited
HER2 kinase activity (Fig. 3d). To model RJLC2 and RJLC3, we
applied this method to KRAS-mutant NCI-H1944 cells and found
that BRAFD594G, c-METΔE14, ARAFS214C, or MEK1E102-I103 del
expression could indeed functionally rescue the depletion of
KRASG13D (Fig. 3e). Similar results were obtained with NCI-
H2009 cells harboring KRASG12A (Supplementary Fig. 13b). We
conclude that the evolutionary trajectories of independent tumors
in MSLC might converge to cause preferential activation of
constrained, critical oncogenic pathways.
Independent validation of oncogenic pathway convergence.
Several complementary lines of evidence further validated this
principle of biologically constrained expansion of somatic genetic
alterations in MSLC development that we uncovered. First, recent
genomic sequencing of small MSLC cohorts revealed frequent
mutational co-occurrence in the same cancer gene among dif-
ferent tumors (Supplementary Table 7), even though these
tumors originated from distinct progenitor cells8, 28. Second, we
retrospectively identified two patients (RJLC5 and RJLC6) with
synchronous lung and breast cancers (Fig. 4a), who underwent
surgical resection of both tumors. We collected fresh tissues for
these patients and conducted whole-genome sequencing (WGS),
revealing independent clonality of lung and breast tumors based
on somatic mutations (Supplementary Fig. 14a). A circos plot
analysis showed no common structural alterations and confirmed
that these synchronous tumors developed through an accumu-
lation of completely different genetic events (Fig. 4b). However,
the two tumors in each patient, albeit from different tissues of
origin, showed remarkably similar mutation spectra and sig-
natures (Supplementary Fig. 14b). In addition, we identified c-
METΔE14, HER2Y777L, EGFR-KDD, and HER4N855K as the most
predominant driver mutants in these four tumors (Fig. 4b; Sup-
plementary Fig. 14c), indicative of the convergent central role of
receptor tyrosine kinases in both lung and breast cancer. Finally,
we were able to test the potential therapeutic implications of our
findings in a pilot prospective study. Patient RJLC7 was hospi-
talized due to persistent acroanesthesia and was subsequently
diagnosed with MSLC, presenting as a number of ground glass
opacities (GGO) spread among three lung lobes. In August 2014,
the patient received a video-assisted thoracoscopic surgery
(VATS)-guided right upper lobectomy, right lower lobe wedge
resection and lymphadenectomy. Two relatively larger lesions
were removed and pathologically graded as pT1N0M0 stage IA
lung adenocarcinomas. WES indicated that RJLC7-T1 and
RJLC7-T2 were multicentric primary tumors (Supplementary
Fig. 15a), but shared identical mutation spectra and signatures
(Supplementary Fig. 15b). Both tumors harbored FGFR3 focal
amplification. Additionally, we detected BRAFN581S in RJLC7-T2
and EGFRL858R in RJLC7-T1 (Fig. 4c), which was confirmed
using amplification refractory mutation system (ARMS).
Although there were several small nodules present as localized
disease in her left upper lobe, the patient declined a secondary
surgical procedure, as well as a biopsy for molecular analysis, and
instead elected to begin gefitinib treatment off-label to address the
possible progression of her early-stage disease. She was monitored
closely with serial imaging and gradual GGO regression was
observed (Fig. 4d). Although these data must be interpreted with
caution, the response to the EGFR-targeted drug suggests an
EGFR signaling dependency in this distinct area of multifocal
disease that is consistent with the activating EGFRL858R mutation
found in RJLC7-T1; these findings provide additional suggestive
evidence of interfocal convergent evolution in MSLC. The patient
remains on therapy without notable adverse effects to date. An
expanded, multicenter clinical investigation has been planned to
determine the extent and significance of convergent tumor evo-
lution in patients with MSLC.
Discussion
When viewed through the lens of evolutionary biology, cancer has
been considered as an incessantly evolving ecosystem involving
dynamic interplay between tumor cells and their microenviron-
ment2. The fittest clones survive and expand, following the
Darwinian rule of natural selection41. Moreover, genetic
instability is an integral component of human neoplasia, and as a
result, stochastic mutagenesis constantly takes place and may
phenotypically alter clonal fitness3. These repeated rounds of new
mutation emergence and pervasive positive and negative selection
make intertumor and intratumor heterogeneity almost inevi-
table42, 43. Indeed, our study has provided genomic portraits of
the interfocal and intrafocal molecular landscape of MSLC, and
revealed a high prevalence of heterogeneity despite a shared
genetic background and environmental exposure in each subject.
These data validate and extend previous findings of pronounced
intratumor heterogeneity observed in non-small cell lung cancer,
which has been speculated to complicate the molecular diagnosis
and therapeutic interference of this deadly disease7, 8.
However, an important question that remains to be addressed is
how much of the genetic heterogeneity will prove to be functionally
relevant and clinically relevant. Interestingly, our study revealed that
most key driver mutations were clonal and the seemingly distinct
multifocal tumors often converged on selected oncogenic pathways
that our evidence suggests are functionally interchangeable. Nota-
bly, we developed a specific experimental workflow based on the
CRISPR-Cas9 system, and formally demonstrated that distinct
genetic alterations harbored by different foci in each MSLC case
imparted equivalent signaling outputs and treatment responses.
These data therefore argue strongly for evolutionary constraints
during lung cancer initiation and progression. Taken together, our
observations highlight the coexistence of genomic diversity and
phenotypic convergence as a possibly generalizable principle for
understanding tumor evolution, which may hold potential impli-
cations for identifying and prioritizing therapeutic strategies. On
one hand, the degree of genetic diversity present in many tumors
and patients necessitates the functional inference of aberrant
oncoprotein activity driving individual tumors or subclones, in
order to apply precise pharmacological inhibition. On the other
hand, the striking functional convergence of heterogeneous cancer-
driving abnormalities may enable the reproducible prediction of
their biological consequence and therapeutic “actionability”.
Importantly, we showed in a pilot study that how this concept could
aid rational therapeutic prioritization against MSLC when a mole-
cular diagnosis was not feasible. Conceivably, similar competing
evolutionary forces may likewise operate during anti-cancer treat-
ment, which, if ultimately validated in prospective clinical investi-
gations, will help formulate strategic guidelines for the management
of anticipated drug resistance.
In conclusion, our findings not only provide the rationale for
employing more sophisticated genomic profiling to distinguish
between potentially curable multiple primary tumors and unre-
sectable metastatic dissemination in patients with MSLC, a dis-
ease with increasing incidence, but also provide initial evidence
for perhaps an underestimated extent of parallel evolution and
recurrent patterns in the spatiotemporal acquisition of driver
mutations during tumorigenesis. A deeper understanding of the
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dueling evolutionary forces that control the simultaneous
expansion and constraint of tumor genomic diversity and het-
erogeneity (please refer to the schematic model shown in Fig. 4e;
also see ref. 44) promises to improve the diagnosis and treatment
of lung cancer and other malignancies.
Methods
Patient cohort description. The study was approved by the Ren Ji Hospital Ethics
Committee. All patients provided written informed consent. Tumor samples for
sequencing were obtained from five patients diagnosed with pathologically con-
firmed multiple synchronous lung cancers (MSLCs). The other two patients were
diagnosed with synchronous lung and breast adenocarcinomas. These patients
underwent surgical resection prior to receiving any form of adjuvant therapy. All
samples were collected in Ren Ji Hospital, Shanghai Jiao Tong University School of
Medicine. Tumor sizes ranged from 0.5 to 3.6 cm according to pathology reports.
All patients were free of extrathoracic metastasis. Detailed clinical characteristics
were provided in Table 1. Eighteen samples from five patients with MSLCs were
subjected to whole-exome sequencing (WES), and four samples from two patients
with lung and breast cancers were subjected to whole-genome sequencing (WGS).
Tumor processing. Up to ten 10 μm fresh frozen sections for each tumor sample
and adjacent normal tissue were selected by a pathologist, documented by pho-
tography, and snap-frozen. Haematoxylin-eosin-stained slides were reviewed by
experienced lung cancer pathologists to determine the histomorphological subtype
and the proportion of malignant cells relative to nonmalignant stromal cells.
Approximately 5 × 5 × 5mm tumor tissues were used for genomic DNA extraction,
using the DNeasy kit (Qiagen) according to manufacturer’s protocol. DNA was
quantified by Qubit (Life Technologies) and DNA integrity was examined by
agarose gel electrophoresis.
Whole-exome sequencing. Paired-end DNA library were prepared according to
manufacturer’s instructions (Agilent). Genomic DNAs (gDNA) from patients
RJLC1 to 4 and RJLC7 were sheared into 180 ~ 280 bp fragments by Covaris
S220 sonicator. Ends of the gDNA fragments were repaired; 3′ ends were adeny-
lated. Both ends of the gDNA fragments were ligated at the 3′ ends with paired-end
adaptors (Illumina) with a single ‘T’ base overhang and purified using AMPure
SPRI beads from Agencourt. The adaptor-modified gDNA fragments were enri-
ched by six cycles of PCR using SureSelect Primer and SureSelect ILM Indexing Pre
Capture PCR Reverse Primer. The concentration and the size distribution of the
libraries were determined on an Agilent Bioanalyzer DNA 1000 chip. Whole-
exome capture was carried out using Agilent’s SureSelect Human All Exon V5 Kit.
An amount of 0.5 μg prepared gDNA library was hybridized with capture library of
biotinylated RNA baits for 5 min at 95 °C, 24 h at 65 °C. The captured DNA−RNA
hybrids were recovered using Dynabeads MyOne Streptavidin T1 from Dynal.
DNA was eluted from the beads and desalted using Qiagen MinElute PCR pur-
ification columns. The purified capture products were then amplified using the
SureSelect ILM Indexing Post Capture Forward PCR Primer and PCR Primer
Index 1 through Index 16 (Agilent) for 12 cycles. 50Mb of DNA sequences of
334,378 exons from 20,965 genes were captured. After DNA quality assessment,
captured DNA library were sequenced on Illumina Hiseq 4000 sequencing plat-
form (Illumina) according to manufacture’s instructions for paired-end 150 bp
reads (Novogene, Beijing). Libraries were loaded onto paired-end flowcells at
concentrations of 14–15 pM to generate cluster densities of 800,000–900,000 per
mm2 using Illumina cBot and HiSeq paired-end cluster kit version 1. The
sequencing depth was 200×.
Whole-genome sequencing. A total amount of 1 μg genomic DNA per sample
was used as input material for the DNA library preparations. Sequencing library
was generated using Truseq Nano DNA HT Sample Prep Kit (Illumina) following
manufacturer’s recommendations and index codes were added to each sample.
Briefly, genomic DNA sample was fragmented by sonication to a size of 350 bp.
Then DNA fragments were end-polished, A-tailed, and ligated with the full-length
adapter for Illumina sequencing, followed by further PCR amplification. After PCR
products were purified with AMPure XP system, libraries were analyzed for size
distribution by Agilent 2100 Bioanalyzer and quantified by real-time PCR (3 nM).
The clustering of the index-coded samples was performed on a cBot Cluster
Generation System using Hiseq PE Cluster Kit (Illumina) according to the man-
ufacturer’s instructions. After cluster generation, the DNA libraries were sequenced
on Illumina Hiseq 4000 sequencing platform (Illumina) and 150 bp paired-end
reads were generated. The sequencing depth was 60×.
Sequence alignment and variant calling. Paired-end clean reads in FastQ format
generated by the Illumina pipeline were aligned to the reference human genome
(UCSC hg19) by Burrows-Wheeler Aligner (BWA) to get the original mapping
results stored in BAM format45. SAMtools46, Picard (http://broadinstitute.github.
io/picard/), and GATK47 were used to sort BAM files and do duplicate marking,
local realignment, and base quality recalibration to generate final BAM files for
computation of the sequence coverage and depth. The somatic SNVs were detected
by VarScan version 2.2.5 and MuTect48, 49, and the somatic InDels detected by
GATK Somatic Indel Detector. ANNOVAR was performed to do annotation for
VCF (Variant Call Format), including querying the databases of dbSNP and the
1000 Genomes Project50. Variant position, variant type, conservative prediction
and other information were obtained at this step. Gene transcript annotation
databases, such as Consensus CDS, RefSeq, Ensembl and UCSC, were applied for
annotation to determine amino acid alternations. Variants obtained from previous
steps were compared against SNPs present in the dbSNP and 1000 Genomes
databases (1000 Genomes Project Consortium) to discard known SNPs. Only SNVs
occurring in exons or in canonical splice sites were further analyzed. The retained
non-synonymous SNVs were submitted to PolyPhen and SIFT for functional
prediction. Control-FREEC was utilized to detect somatic CNV51. For samples
from patient RJLC5 and RJLC6, which were subjected to WGS, breakdancer was
implemented to identify potential structural variants52. All these variant results
were visualized using Circos53.
Identification of putative driver mutations. All identified non-silent mutations
were compared with lists of potential driver genes in NSCLC, containing all genes
identified as frequently mutated by large-scale lung cancer sequencing studies or
large-scale pan-cancer analyses using q < 0.05 as cutoff, or present in the COSMIC
cancer gene census (August 2015). Next, non-silent variants in these genes were
evaluated, and putative driver mutations were identified if they met one of the
following requirements: (1) either the exact mutation, the same mutation site or at
least three mutations located within 15 bp of the variant were found in COSMIC
and (2) if the candidate gene was marked as recessive in COSMIC and the variant
was predicted to be deleterious, including stop-gain, frameshift and splicing
mutation, and had a SIFT score< 0.05 or a PolyPhen score> 0.995. Then, the
putative driver mutations were subjected to Sanger sequencing for validation when
adequate DNA was available. The mutated protein structures were generated by
Phyre2 web portal. All figures were prepared by using PyMOL (http://pymol.
sourceforge.net/).
Mutational signature analysis. Both silent and non-silent somatic SNVs were
measured to define mutational signatures in the tumors. For each tumor, we
extracted the 5′ and 3′ sequence context of each mutation from the hg19 reference
genome and the SNVs were categorized into C>A, C>G, C> T, T >A, T >C,
and T>G bins according to the type of substitution and then subcategorized into
96 sub-bins according to the nucleotides preceding (5′) and succeeding (3′) the
mutated base. To enable comparison with the known signatures based on the
Wellcome Trust Sanger Institute Mutational Signature Framework, the R package
‘deconstructSigs’ was used to statistically quantify the contribution of each sig-
nature for each tumor32.
Clonality analysis. PyClone and SciClone were employed to detect subclones.
PyClone applied an MCMC method to cluster variants. SciClone focused primarily
on variants in copy number neutral, loss of heterozygosity (LOH)-free portions of
the genome, which allows for the highest confidence quantification of variant allele
frequencies (VAF) and inference of clonality.
Cancer cell fraction analysis. For each variant, the expected VAF, given the
cancer cell fraction (CCF), was defined as f CCFð Þ ¼ p ´CCFCPNmut ´ pþCPNnorm 1pð Þ, where
CPNmut corresponds to the local copy number of the tumor, CPNnorm is the local
copy number of the matched normal sample and p is the tumor purity. Tumor
cellularity was determined on the basis of VAF and segmented copy number data
using ABSOLUTE54, to calculate the CCF of each mutation. Clonal status was
defined according to the confidence interval of CCF.
Neoantigen prediction. HLA typing was performed using Polysolver55. Non-silent
mutations served as basis to generate a list of peptides ranging 9–11 amino acids in
length with the mutated residues represented in each position. Prediction for
binding affinity of every mutant peptide and its corresponding wild-type peptide to
the patient’s germline HLA alleles was performed using the NetMHCpan algorithm
(v3.0)56. Candidate neoantigens were identified as those with a predicted mutant
peptide binding affinity of < 500 nM and less than that of its corresponding wild-
type peptide.
Cell culture and reagents. Tumor cell lines were obtained from ATCC or JCRB,
where cell characterization (polymorphic short tandem repeat profiling) and
contamination were performed. Cells were cultured in RPMI1640 (Invitrogen)
supplemented with 10% fetal bovine serum (Gibco). Erlotinib, afatinib, doc-
amatinib, trametinib, dabrafenib, and lapatinib were purchased from Selleck
Chemicals. All inhibitors were reconstituted in DMSO (Sigma-Aldrich) at a stock
concentration of 10 mM. For cell viability assays, cells were seeded at 100,000 cells
per well in growth media supplemented with 10% FBS and 2 mM L-glutamine in 6-
well plate, allowed to adhere overnight, and treated with a serial dilution of inhi-
bitors for 1 week. Cells were fixed with formalin, and stained with crystal violet.
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CRISPR-Cas9 knockout. CRISPR-Cas9 knockout technology was employed to
knockout EGFR or KRAS in PC9 or H1944 and H2009 cells, respectively. We
constructed LentiCRISPR v2 vector with blasticidin resistance, designed sgRNA
and constructed lentiviral CRISPR plasmids according to the previously described
protocol57. EGFR-sgRNA: 5′-CACCGCTGCGCTCTGCCCGGCGAGT-3′ and
5′-AAACACTCGCCGGGCAGAGCGCAGC-3′; KRAS-sgRNA: 5′-CACCGT-
CTCGACACAGCAGGTCAAG-3′ and 5′-AAACCTTGACCTGCTGTGTCGA-
GAC-3′. An EGFP-sgRNA (5′-CACCGGAAGTTCGAGGGCGACACCC-3′ and
5′-AAACGGGTGTCGCCCTCGAACTTCC-3′) was used as negative control.
Western blot. Cells or tissues were lysed in RIPA buffer (Tris pH 7.4 50 mM, NaCl
150 mM, NP-40 1%, SDS 0.1%, EDTA 2 μM) containing proteinase inhibitors
(Roche) and phosphatase inhibitors (Roche). The lysates (20 μg protein) were
subjected to SDS-PAGE and western blot. Antibodies against the following proteins
were used: phospho-EGFR (Y1068), EGFR, phospho-MEK1/2 (S217/221), MEK1/
2, phospho-ERK (T202/Y204), ERK, phospho-AKT (T308), phospho-AKT (S473),
AKT, phospho-HER2 (Y1221/1222), HER2, MET, HER4, HER3, PDGFRB, H3 and
Rab11 (Cell Signaling Technology). Antibodies against ARAF and BRAF were
purchased from Santa Cruz. Anti-RAS antibody was purchased from Millipore.
Uncropped images of the immunoblots were shown in Supplementary Fig. 16.
Immunohistochemistry. Immunohistochemistry was performed using 5 μm-thick,
formalin-fixed, paraffin-embedded tissue sections. Slides were baked, depar-
affinized in xylene, passed through graded alcohols, and antigen retrieved with 10
mM citrate buffer, pH 6.0 in a steam pressure cooker. Preprocessed tissues were
treated with peroxidase block (Dako) to quench endogenous peroxidase activity,
blocked using protein block (Dako), and incubated with indicated antibodies. Slides
were then washed in 50 mM Tris-Cl, pH 7.4 and incubated with horseradish
peroxidase-conjugated secondary antibody. Immunoperoxidase staining was
developed using a 3,3′diaminobenzidine (DAB) chromogen. Slides were counter-
stained with hematoxylin, dehydrated in graded alcohol and xylene, and cover-
slipped using mounting solution.
Tumor xenograft and PDX models. Tumor cells (1 × 106) were mixed with
Matrigel (BD Biosciences) and subcutaneously implanted in the dorsal flank of
BALB/c nude mice. When tumor sizes reached ~ 150mm3, animals were rando-
mized into two groups of 10 mice each. One group of mice was treated with vehicle
control (0.5% methylcellulose and 0.2% Tween-80), and the other group was
treated with trametinib (1 mg per kg per day). Tumor volumes (10 animals per
group) were measured with digital caliper and calculated as length × width2 × 0.52.
The animals were housed in a specific pathogen free (SPF) animal facility in
accordance with the Guide for Care and Use of Laboratory Animals and the
regulations of the Institutional Animal Care and Use Committee in Ren Ji Hospital.
Lung PDX model was established using patient tumor tissues acquired during
surgery. Prior written informed consent was obtained from the patient. Experi-
ments were conducted on female BALB/c nude mice aged 6–8 weeks old. Freshly
collected tumor samples were cut into small pieces and implanted subcutaneously
to the flanks of nude mice. Tumors used in this study were over passage-3 with
stable tumor growth. Tumor-bearing mice with tumors at 100–250 mm3 range
were selected and randomly divided into four groups of 10 mice each. One group of
mice was treated with vehicle control (0.5% methylcellulose and 0.2% Tween-80),
and the other three groups were treated with dabrafenib (30 mg per kg per day),
trametinib (1 mg per kg per day) and a combination of both drugs, respectively.
Tumor volumes (10 animals per group) were measured with digital caliper and
calculated as length × width2 × 0.52.
Statistical analysis. Statistical analysis was performed with GraphPad Prism
software. In all experiments, comparisons between two groups were based on two-
sided Student’s t-test and one-way analysis of variance (ANOVA) was used to test
for differences among more groups. P-values of < 0.05 were considered statistically
significant.
Data availability. The sequencing data have been deposited in NCBI SRA database
(http://www.ncbi.nlm.nih.gov/SRA/) under the accession number SRP095985. All
other data are included within the article or available from the authors upon
request.
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